Search results
Results from the WOW.Com Content Network
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. [3] [4] It is used in combination with nivolumab to treat melanoma. [2] [5] Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. [2] [5] It is under development by Bristol-Myers Squibb. [2] [5] It is made using Chinese hamster ovary cells. [2]
Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. [5] LAG3, which was discovered in 1990 [6] and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, [7] is a cell surface molecule with diverse biological effects on T cell function but overall has an immune ...
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. [10] It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. [10] It is given by intravenous infusion. [10]
Patients with previously untreated melanoma that had spread or could not be removed by surgery who received relatlimab plus Opdivo on average went 10.1 months before the deadly skin cancer began ...
Pharmaceutical giant GlaxoSmithKline announced in a press release that it has begun a phase 3 study to find out whether two of its drugs -- its BRAF inhibitor dabrafenid and MEK inhibitor ...
LAG-3 Inhibitors. In 2022, the FDA approved a combination of relatlimab and nivolumab to be marketed under the name Opdualag for people aged 12 or older with previously untreated melanoma that cannot be removed surgically or has spread (metastasized) within the body. Relatlimab blocks a protein on immune cells called LAG-3. [22]
For premium support please call: 800-290-4726 more ways to reach us
Eftilagimod alpha ("efti" in short) is a soluble LAG-3 fusion protein that activates antigen-presenting cells. It is a 160 kDa protein consisting of the four extracellular domains of LAG-3 fused to the Fc region of an IgG1(LAG-3Ig). Efti binds preferentially to a subset of MHC class II molecules that are enriched in lipid rafts and/or composed ...